Polypharmacy and prevalence of multi drug-drug interactions in hepatitis C patients treated with pangenotypic direct acting antivirals: an analysis from three European countries
Por:
Tacke, F, Turnes, J, Hintz, A, Fagiuoli, S, Sicras-Mainar, A, Umland, T, Degli Esposti, L, Verdugo, R, Herola, A, Guendogdu, M, Mendez, M, Nieto, G, Vanstraelen, K, Hernandez, C and Mangia, A
Publicada:
1 jul 2022
Categoría:
Hepatology
Resumen:
Filiaciones:
Tacke, F:
Charite Univ Med Berlin, Berlin, Germany
Turnes, J:
Complejo Hosp Univ Pontevedra, Gastroenterol & Hepatol, Pontevedra, Spain
Hintz, A:
Alexander Apotheke, Hamburg, Germany
Fagiuoli, S:
ASST Papa Giovanni XXIII Hosp, Bergamo, Italy
Sicras-Mainar, A:
Atrys Hlth, HEOR, Barcelona, Spain
Umland, T:
Alexander Apotheke, Hamburg, Germany
Degli Esposti, L:
Clicon Srl, Hlth Econ & Outcomes Res, Ravenna, Italy
Verdugo, R:
Hosp Univ Valme, Seville, Spain
:
Hosp Marina Baixa, Villajoyosa, Spain
Guendogdu, M:
Gilead Sci GmbH, Med Affairs, Munich, Germany
Mendez, M:
Gilead Sci SL, Med Affairs, Madrid, Spain
Nieto, G:
Gilead Sci Srl, Med Affairs, Milan, Italy
Vanstraelen, K:
Gilead Sci, Global Med Affairs, Milan, Italy
Hernandez, C:
Gilead Sci, Global Med Affairs, Milan, Italy
Mangia, A:
Fdn Casa Sollievo, San Giovanni Rotondo, Italy
|